



MAIL DATE CANCELLED



Attachment
09/595682
5
Sheet 01 of 04

Form PTO-1449 Modified

List of Patents and Publications
Cited by Applicant
(Use several sheets if necessary)

U.S. Department of Commerce

Docket No.
SJ-0005

Serial No. **09/595,682**

Applicant
DANKS ET AL.

JAN 10 2001

Filing Date
JUNE 16, 2000

Group
1643

TECH CENTER 1600/2900

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

CA	AA	Bello-Fernandez, C., et al., "The ornithine decarboxylase gene is a transcriptional target of c-Myc", 1993 Proc. Natl. Acad. Sci. USA 90:7804-7808
	AB	Brodeur, G.M., et al., "Biology and Genetics of Human Neuroblastomas", 1997 J. Ped. Hematol. Oncol. 19:93-101
	AC	Dachs et al., "Targeting Gene Therapy to Cancer: A Review", 1997 Oncol. Res. 9:313-325
	AD	Davis et al., "Current progress in the gene therapy of cancer", 1996 Current Opinion in Oncology 8:499-508
	AE	Field, et al., "Elevated expression of the c-myc oncoprotein correlates with poor prognosis in head and neck squamous cell carcinoma", 1989 Oncogene 4:1463-1468
	AF	Haaz, M.C., et al., "Metabolism of Irinotecan (CPT-11) by Human Hepatic Microsomes: Participation of Cytochrome P-450 3A and Drug Interactions ¹ ", 1998 Cancer Res. 58:468-472
	AG	Hanania et al., "Recent Advances in the Application of Gene Therapy to Human Disease", 1995 Am. Jour. Med. 99:537-552
	AH	Houghton, P.J., et al., "Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors", 1995 36:393-403
	AI	Houghton, P.J., et al., "Therapeutic Efficacy of the Topoisomerase I Inhibitor 7-Ethyl-10-(4-([1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against Human Tumor Xenografts: Lack of Cross-Resistance in Vivo in Tumors with Acquired Resistance to the Topoisomerase I Inhibitor 9-Dimethylaminomethyl-10-hydroxycamptothecin ¹ ", 1993 53:2823-2829

EXAMINER

DATE CONSIDERED

11/17/02

MAIL DATE CANCELLED

RECEIVED

Sheet 02 of 04

Form PTO-1449 Modified List of Patents and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce	Docket No. SJ-0005	Serial No. 09/595,682
	Applicant DANKS ET AL.	
	Filing Date JUNE 16, 2000	Group 1643



OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

CA	AJ	Hsiang, Y.-H. et al., "Arrest of Replication Forks by Drug-stabilized Topoisomerase I-DNA Cleavable Complexes as a Mechanism of Cell Killing by Camptothecin", 1989 <i>Cancer Res.</i> 49:5077-5082
	AK	Humerickhouse et al., "Characterization of CPT-11 Hydrolysis by Human Liver Carboxylesterase Isoforms hCE-1 and hCE-2 ¹ ", 2000 <i>Cancer Res.</i> 60:1189-1192
	AL	Johnson et al., "Current therapy for cutaneous melanoma", 1995 <i>J. Am. Acad. Derm.</i> 32(5):689-707
	AM	Kaneda, N. et al., "Metabolism and Pharmacokinetics of the Camptothecin Analogue CPT-11 in the Mouse", 1990 <i>Cancer Res.</i> 50:1715-1720
	AN	Kawasaki, H. et al., "Specific Regulation of Gene Expression by Antisense Nucleic Acids: A Summary of Methodologies and Associated Problems", 1996 <i>Artif. Organs</i> 20(8):836-848
	AO	Kawato, Y. et al., "Intracellular Roles of SN-38, a Metabolite of the Camptothecin Derivative CPT-11, in the Antitumor Effect of CPT-11", 1991 <i>Cancer Res.</i> 51:4187-4191
	AP	Korza, G. and J. Ozols, "Complete Covalent Structure of 60-kDa Esterase Isolated from 2,3,7,8-Tetrachlorodibenzo-p-dioxin-induced Rabbit Liver Microsomes" 1988 <i>J. Biol. Chem.</i> 263:3486-3495
	AQ	Kumagai, T. et al., "Eradication of Myc-overexpressing Small Cell Lung Cancer Cells Transfected with Herpes Simplex Virus Thymidine Kinase Gene Containing Myc-Max Response Elements ¹ ", 1996 <i>Cancer Res.</i> 56(2):354-358
✓	AR	Leinweber, F.J., "Possible Physiological Roles of Carboxylic Ester Hydrolases", 1987 <i>Drug Metab. Rev.</i> 18:379-439

EXAMINER

DATE CONSIDERED

1/17/02



Sheet 03 of 04



Form PTO-1449 Modified List of Patents and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce	Docket No. SJ-0005	Serial No. 09/595,982
	Applicant DANKS ET AL.	
	Filing Date JUNE 16, 2000	Group 1643 TECH CENTER 1600/2900

RECEIVED**JAN 10 2001****OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

CA	AS	Lutz et al., "Conditional expression of N-myc in human neuroblastoma cells increases expression of α -prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells", 1996 <i>Oncogene</i> 13:803-812
	AT	Matthay, K.E., "Neuroblastoma: Biology and Therapy", 1997 <i>Oncology</i> 11:1857-1875
	AU	Matthay, K.E., et al., "Patterns of Relapse After Autologous Purged Bone Marrow Transplantation for Neuroblastoma: A Childrens Cancer Group Pilot Study", 1993 <i>J. Clin. Oncol.</i> 11:2226-2233
	AV	Nagai, M.A., et al., "Association of Genetic Alterations of c-myc, c-fos, and c-Ha-ras Proto-Oncogenes in Colorectal Tumors", 1992 <i>Dis. Colon Rectum</i> 35:444-451
	AW	Orian, J.M., et al., "Overexpression of multiple oncogenes related to histological grade of astrocytic glioma", 1992 <i>Br. J. Cancer</i> 66:106-112
	AX	Raschella, G., et al., "Lack of Correlation between N-myc and MAX Expression in Neuroblastoma Tumors and in Cell Lines: Implication for N-myc-MAX Complex Formation", 1994 <i>Cancer Res.</i> 54:2251-2255
	AY	Rill, D.R., et al., "Direct Demonstration That Autologous Bone Marrow Transplantation for Solid Tumors Can Return a Multiplicity of Tumorigenic Cells", 1994 <i>Blood</i> 84:380-383
	AZ	Riou, G., et al., "C-myc PROTO-ONCOGENE EXPRESSION AND PROGNOSIS IN EARLY CARCINOMA OF THE UTERINE CERVIX", 1987 <i>Lancet</i> 2:761-763
✓	BA	Rivory, et al., "Identification and Properties of a Major Plasma Metabolite of Irinotecan (CPT-11) Isolated from the Plasma of Patients", 1996 <i>Cancer Res.</i> 56:3689-3694

EXAMINER**DATE CONSIDERED**

1/17/02



Sheet 04 of 04

Form PTO-1449 Modified

Docket No.
SJ-0005Serial No.
09/595,688

RECEIVED

List of Patents and Publications
Cited by Applicant
(Use several sheets if necessary)Applicant
DANKS ET AL.

JAN 10 2001

U.S. Department of Commerce

Filing Date
JUNE 16, 2000Group
1643

TECH CENTER 1600/2900

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

cQ	BB	Rivory, L.P., et al., "Pharmacokinetic Interrelationships of Irinotecan (CPT-11) and Its Three Major Plasma Metabolites in Patients Enrolled in Phase I/II Trials", 1997 Clin. Cancer Res. 56:3689-3694
	BC	Roth and Cristiano, "Gene Therapy for Cancer: What Have We Done and Where Are We Going?", 1997 J. Natl. Canc. Inst. 89(1):21-39
	BD	Rowinsky, E.K., et al., "Phase I and Pharmacological Study of the Novel Topoisomerase I Inhibitor 7-Ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) Administred as a Ninety-Minute Infusion Every 3 Weeks", 1994 Cancer Res. 54:427-436
	BE	Satoh, T., et al., "Metabolic Activation of CPT-11, 7-Ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin, a Novel Antitumor Agent, by Carboxylesterase" 1994 Biol. Pharm. Bull. 17:662-664
	BF	Senter, P.D., et al., "The Role of Rat Serum Carboxylesterase in the Activation of Paclitaxel and Camptothecin Prodrugs", 1996 Cancer Res. 56:1471-1474
	BG	Tanizawa, A., et al., "Comparison of Topoisomerase I Inhibition, DNA Damage, and Cytotoxicity of Camptothecin Derivatives Presently in Clinical Trials", 1994 J. Natl. Cancer Inst. 86:836-842
	BH	Tsuji, T., et al., "CPT-11 Converting Enzyme from Rat Serum: Purification and Some Properties", 1991 J. Pharmacobio. Dynamics 14:341-349
	BI	Yamada, H., et al., "AMPLIFICATIONS OF BOTH c-Ki-ras WITH A POINT MUTATION AND c-myc IN A PRIMARY PANCREATIC CANCER AND ITS METASTATIC TUMORS IN LYMPH NODES", 1986 Jpn. J. Cancer Res. 77:370-375
✓	BJ	Yang, N.S., "Gene Transfer into Mammalian Somatic Cells In Vivo", 1992 Crit. Rev. Biotechnol. 12:335-356

EXAMINER

DATE CONSIDERED

1/17/02